Your browser doesn't support javascript.
loading
An adapted consensus protein design strategy for identifying globally optimal biotherapeutics.
Liu, Yanyun; Tsang, Kenny; Mays, Michelle; Hansen, Gale; Chiecko, Jeffrey; Crames, Maureen; Wei, Yangjie; Zhou, Weijie; Fredrick, Chase; Hu, James; Liu, Dongmei; Gebhard, Douglas; Huang, Zhong-Fu; Datar, Akshita; Kronkaitis, Anthony; Gueneva-Boucheva, Kristina; Seeliger, Daniel; Han, Fei; Sen, Saurabh; Kasturirangan, Srinath; Scheer, Justin M; Nixon, Andrew E; Panavas, Tadas; Marlow, Michael S; Kumar, Sandeep.
  • Liu Y; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Tsang K; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Mays M; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Hansen G; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Chiecko J; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Crames M; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Wei Y; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Zhou W; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Fredrick C; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Hu J; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Liu D; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Gebhard D; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Huang ZF; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Datar A; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Kronkaitis A; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Gueneva-Boucheva K; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Seeliger D; Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
  • Han F; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Sen S; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Kasturirangan S; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Scheer JM; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Nixon AE; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Panavas T; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Marlow MS; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
  • Kumar S; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.
MAbs ; 14(1): 2073632, 2022.
Article en En | MEDLINE | ID: mdl-35613320
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Anticuerpos Monoclonales Tipo de estudio: Guideline Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Anticuerpos Monoclonales Tipo de estudio: Guideline Idioma: En Año: 2022 Tipo del documento: Article